Secoisolariciresinol diglucoside

Drug Profile

Secoisolariciresinol diglucoside

Alternative Names: SDG

Latest Information Update: 30 Apr 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Saskatchewan
  • Class Antifibrotics; Chemoprotectants; Glycosides; Lignans; Small molecules
  • Mechanism of Action Antioxidants; Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis; Hypercholesterolaemia; Hypertension

Most Recent Events

  • 19 Aug 2003 This compound is still in active development
  • 19 Jun 2003 Preclinical trials in Hypertension in Canada (unspecified route)
  • 21 May 2003 SDG has been licensed to Archer Daniel Midlands worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top